Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03477825 · ClinicalTrials.gov registry record · NA
Pilot Study of Triphala and Rubia Cordifolia on Gut Microbiome and Skin
A NA study of Erythema and Wrinkles, sponsored by University of California, Davis.
- Completed
- Registry status
- NA
- Development phase
- 35
- Enrollment target
- 1
- Study location
NCT03477825: Completed NA study of Erythema and Wrinkles, sponsored by University of California, Davis.
NCT03477825 is a NA study of Erythema and Wrinkles that has completed, run by University of California, Davis. The registered enrollment target is 35 participants, below the 105-participant average among 9 other Erythema trials with a reported enrollment target (67% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03477825, a NA study of Erythema and Wrinkles, has completed, sponsored by University of California, Davis.
- COMPLETED
- Registry status
- NA
- Development phase
- 35 participants
- Enrollment target
- 1
- Study location
Study Summary
Few studies have assessed the effects of Triphala and Rubia Cordifolia from a skin biophysical perspective. Here, we aim to understand how these herbs can modulate the skin's barrier properties and the gut microbiome.
Primary Outcome
Sebum production measured by sebumeter
Conditions Studied
Interventions
- DIETARY_SUPPLEMENT Placebo Oral Tablet
- DIETARY_SUPPLEMENT Rubia Cordifolia
- DIETARY_SUPPLEMENT Triphala
Study Locations (1)
California
- University of California-Davis, Department of Dermatology - Sacramento
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 35 participants |
| Start Date | 2018-03-12 |
| Est. Completion | 2019-01-25 |
| Phase | NA |
What the finished NCT03477825 record still lists
NCT03477825 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 35 participants, a relatively small participant target, below the 105-participant average among 9 other Erythema trials with a reported enrollment target (67% lower).
The record links to 7 conditions, with Erythema appearing as the primary indexed condition, and to 3 interventions - of which Placebo Oral Tablet is the first listed.
NCT03477825 reports a single indexed study location in California.
Frequently Asked Questions
What is clinical trial NCT03477825 about?
NCT03477825 is a clinical study titled "Pilot Study of Triphala and Rubia Cordifolia on Gut Microbiome and Skin". Few studies have assessed the effects of Triphala and Rubia Cordifolia from a skin biophysical perspective. Here, we aim to understand how these herbs can modulate the skin's barrier properties and the gut microbiome.
What is the current status of trial NCT03477825?
This trial is currently completed. It is a NA study. The enrollment target is 35 participants. The study started on 2018-03-12. Estimated completion is 2019-01-25.
What conditions does trial NCT03477825 study?
This clinical trial studies the following conditions: Erythema, Wrinkles, Sebum Production, Stool Microbiome, Transepidermal Water Loss.
What interventions are being tested in trial NCT03477825?
The interventions under investigation include: Placebo Oral Tablet (DIETARY_SUPPLEMENT), Rubia Cordifolia (DIETARY_SUPPLEMENT), Triphala (DIETARY_SUPPLEMENT).
Who is sponsoring clinical trial NCT03477825?
This trial is sponsored by University of California, Davis, which has 657 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03477825 being conducted?
This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Erythema
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT03477825's enrollment target sits among peer trials
35 8th of 9 higher than 2 of 9 other Erythema trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Erythema trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Human Repeat Insult Patch Test to Evaluate Personal Lubricants
COMPLETED · NA
-
A Comparison of INSORB Staples With Metal Staples in Total Hip Replacement
COMPLETED · NA
-
A Single-Center, Clinical Study to Evaluate the Safety of a Fragranced Personal Lubricant in Healthy Female Subjects
COMPLETED · NA
-
A Single-Center, Clinical Study to Evaluate the Safety of a New Personal Lubricant in Healthy Female Subjects
COMPLETED · NA
-
Pembrolizumab in Treating Patients With Stage IV Metastatic or Recurrent Inflammatory Breast Cancer or Triple-Negative Breast Cancer Who Have Achieved Clinical Response or Stable Disease to Prior Chemotherapy
ACTIVE NOT RECRUITING · Phase 2
-
Carboplatin and Paclitaxel With or Without Panitumumab in Treating Patients With Invasive Triple Negative Breast Cancer
ACTIVE NOT RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01697371 · 35 participants · NA
Proton Therapy in the Treatment of Liver Metastases
- NCT01940757 · 35 participants · Phase 1
Experimental Infection of Hookworm-naïve Adults With Dermally-applied Infectious Necator Americanus Hookworm Larvae
- NCT02235857 · 35 participants · NA
Post Approval Study of Liposorber LA-15 System for the Treatment of Focal Segmental Glomerulosclerosis in Children
- NCT02637934 · 35 participants · Phase 1
Phase I Pilot Study of Biodistribution, Metabolism and Excretion of Novel Radiotracer [18F]Fluorthanatrace (FTT) by PET/CT
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI